45.75
price down icon0.33%   -0.15
pre-market  Pre-market:  46.20   0.45   +0.98%
loading
Vera Therapeutics Inc stock is traded at $45.75, with a volume of 372.89K. It is down -0.33% in the last 24 hours and up +11.15% over the past month. Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$45.90
Open:
$46.11
24h Volume:
372.89K
Relative Volume:
0.51
Market Cap:
$2.93B
Revenue:
-
Net Income/Loss:
$-107.85M
P/E Ratio:
-13.62
EPS:
-3.36
Net Cash Flow:
$-106.82M
1W Performance:
-7.44%
1M Performance:
+11.15%
6M Performance:
+11.61%
1Y Performance:
+238.89%
1-Day Range:
Value
$44.97
$46.46
1-Week Range:
Value
$43.41
$50.19
52-Week Range:
Value
$12.28
$51.61

Vera Therapeutics Inc Stock (VERA) Company Profile

Name
Name
Vera Therapeutics Inc
Name
Phone
650-770-0077
Name
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Name
Employee
82
Name
Twitter
Name
Next Earnings Date
2024-08-08
Name
Latest SEC Filings
Name
VERA's Discussions on Twitter

Compare VERA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
VERA 45.75 2.93B 0 -107.85M -106.82M -3.36
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-25-24 Initiated Oppenheimer Outperform
Jan-08-24 Initiated Cantor Fitzgerald Overweight
Dec-18-23 Initiated Raymond James Outperform
Nov-10-23 Upgrade Jefferies Hold → Buy
Aug-16-23 Initiated Guggenheim Buy
Jan-04-23 Downgrade Jefferies Buy → Hold
Jan-04-23 Downgrade Wedbush Outperform → Neutral
Jul-12-22 Initiated JP Morgan Overweight
May-02-22 Initiated H.C. Wainwright Buy
Apr-19-22 Initiated Wedbush Outperform
View All

Vera Therapeutics Inc Stock (VERA) Latest News

pulisher
Nov 20, 2024

GSA Capital Partners LLP Has $535,000 Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat

Nov 20, 2024
pulisher
Nov 20, 2024

Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Calif. Biotech Firm Vera Taps Veteran Chief Legal Officer - Law360

Nov 19, 2024
pulisher
Nov 19, 2024

First Turn Management LLC Increases Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat

Nov 19, 2024
pulisher
Nov 18, 2024

Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer - GlobeNewswire

Nov 18, 2024
pulisher
Nov 18, 2024

Vera Therapeutics Appoints Former Kite Pharma Legal Head as Chief Legal Officer | VERA Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 15, 2024

(VERA) Proactive Strategies - Stock Traders Daily

Nov 15, 2024
pulisher
Nov 15, 2024

COMMODORE CAPITAL LP Adjusts Stake in Vera Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Kynam Capital Management, LP Increases Stake in Vera Therapeutics Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

500: Something went wrong - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

Vera Therapeutics stock soars to all-time high of $50.98 - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

Vera Therapeutics stock soars to all-time high of $50.98 By Investing.com - Investing.com Australia

Nov 14, 2024
pulisher
Nov 13, 2024

Vera Therapeutics (NASDAQ:VERA) Reaches New 1-Year HighHere's What Happened - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC Reduces Stake in Vera Therapeutics Inc - GuruFocus.com

Nov 13, 2024
pulisher
Nov 11, 2024

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 11, 2024
pulisher
Nov 11, 2024

Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study - The Manila Times

Nov 11, 2024
pulisher
Nov 11, 2024

Vera Therapeutics Awards $45.17 Stock Options to New Hires in Growth Push | VERA Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 09, 2024

Vera Therapeutics (NASDAQ:VERA) Posts Quarterly Earnings Results, Misses Expectations By $0.21 EPS - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Vera Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewswire

Nov 08, 2024
pulisher
Nov 08, 2024

Vera Therapeutics to Present at Two Major Healthcare Investor Conferences | VERA Stock News - StockTitan

Nov 08, 2024
pulisher
Nov 08, 2024

Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $38.00 - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Vera Therapeutics Advances in Autoimmune Treatment - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Buy" by Brokerages - MarketBeat

Nov 07, 2024
pulisher
Nov 05, 2024

JPMorgan Chase & Co. Boosts Vera Therapeutics (NASDAQ:VERA) Price Target to $75.00 - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Trading (VERA) With Integrated Risk Controls - Stock Traders Daily

Nov 05, 2024
pulisher
Nov 01, 2024

Vera Therapeutics (NASDAQ:VERA) Shares Up 7.3%Here's Why - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

Vera Therapeutics announces proposed public offering of class A common stock - MSN

Oct 31, 2024
pulisher
Oct 30, 2024

Vera Therapeutics director Beth Seidenberg sells shares for $720,493 - Investing.com India

Oct 30, 2024
pulisher
Oct 30, 2024

Vera Therapeutics director Beth Seidenberg sells shares for $720,493 By Investing.com - Investing.com Canada

Oct 30, 2024
pulisher
Oct 30, 2024

Vera Therapeutics (NASDAQ:VERA) Sees Large Volume IncreaseHere's What Happened - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Vera Therapeutics (NASDAQ:VERA) PT Raised to $64.00 at Guggenheim - Defense World

Oct 30, 2024
pulisher
Oct 29, 2024

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - GlobeNewswire

Oct 29, 2024
pulisher
Oct 29, 2024

Vera Therapeutics (NASDAQ:VERA) Shares Gap DownHere's Why - MarketBeat

Oct 29, 2024
pulisher
Oct 29, 2024

Vera Therapeutics price target raised to $64 from $56 at Guggenheim - Yahoo Finance

Oct 29, 2024
pulisher
Oct 29, 2024

SEC Form 424B5 filed by Vera Therapeutics Inc. - Quantisnow

Oct 29, 2024
pulisher
Oct 28, 2024

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - The Manila Times

Oct 28, 2024
pulisher
Oct 28, 2024

Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $64.00 - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years - AOL

Oct 28, 2024
pulisher
Oct 28, 2024

Vera Therapeutics (NASDAQ:VERA) Shares Gap UpHere's What Happened - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Vera Therapeutics Shares Climb 14% on Positive Results in Kidney Disease Study - MarketWatch

Oct 28, 2024
pulisher
Oct 28, 2024

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga

Oct 28, 2024
pulisher
Oct 28, 2024

Vera reports long-term atacicept data at Kidney Week 2024 - The Pharma Letter

Oct 28, 2024
pulisher
Oct 27, 2024

VERAVera Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 27, 2024
pulisher
Oct 26, 2024

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 - The Manila Times

Oct 26, 2024
pulisher
Oct 26, 2024

Vera Therapeutics Announces 96-week eGFR Stabilization in - GlobeNewswire

Oct 26, 2024

Vera Therapeutics Inc Stock (VERA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):